These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33492224)

  • 1. [Building the scientific commons. Conflictualities and pluralism in the light of clinical trials Covid-19].
    Israel-Jost V; Coutellec L
    Med Sci (Paris); 2021 Jan; 37(1):89-96. PubMed ID: 33492224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 3. Transfusion services operations during the COVID-19 pandemic: Results from AABB survey.
    Pagano MB; Rajbhandary S; Nunes E; Cohn CS
    Transfusion; 2020 Nov; 60(11):2760-2762. PubMed ID: 33217023
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19: Transmission, prevention, and potential therapeutic opportunities.
    Lotfi M; Hamblin MR; Rezaei N
    Clin Chim Acta; 2020 Sep; 508():254-266. PubMed ID: 32474009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):296-298. PubMed ID: 34102319
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
    Abrams-Downey A; Saabiye J; Vidaurrazaga M
    Eur Urol Focus; 2020 Sep; 6(5):1028-1031. PubMed ID: 32563675
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies.
    Hassan M; Zalkifal M; Wahab A; Afzal S; Rafique S; Shahid M; Khan MA; Ahmed N; Idrees M; Shahid AA
    Crit Rev Eukaryot Gene Expr; 2021; 31(3):21-34. PubMed ID: 34369712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 clinical trials: learning from exceptions in the research chaos.
    Tikkinen KAO; Malekzadeh R; Schlegel M; Rutanen J; Glasziou P
    Nat Med; 2020 Nov; 26(11):1671-1672. PubMed ID: 32963376
    [No Abstract]   [Full Text] [Related]  

  • 9. Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City.
    Gulick RM; Sobieszczyk ME; Landry DW; Hollenberg AN
    J Clin Invest; 2020 Sep; 130(9):4522-4524. PubMed ID: 32692726
    [No Abstract]   [Full Text] [Related]  

  • 10. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
    Garraud O; Burnouf T
    Transfus Clin Biol; 2021 Aug; 28(3):225-227. PubMed ID: 34362557
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fight against COVID-19: market overview and pipeline of ongoing trials].
    Pontremoli R; Richard G; Vuddamalay G; Groux N
    Med Sci (Paris); 2020 Dec; 36(12):1225-1232. PubMed ID: 33211647
    [No Abstract]   [Full Text] [Related]  

  • 12. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
    Boiardi F; Stebbing J
    EBioMedicine; 2021 Jan; 63():103170. PubMed ID: 33340994
    [No Abstract]   [Full Text] [Related]  

  • 13. Current Scenario and Future Prospect in the Management of COVID-19.
    Borah P; Deb PK; Deka S; Venugopala KN; Singh V; Mailavaram RP; Kalia K; Tekade RK
    Curr Med Chem; 2021; 28(2):284-307. PubMed ID: 32900341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research.
    Lynch HF; Bateman-House A; Joffe S
    Ann Intern Med; 2021 Feb; 174(2):256-257. PubMed ID: 33136427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving forward in clinical research with master protocols.
    Park JJH; Dron L; Mills EJ
    Contemp Clin Trials; 2021 Jul; 106():106438. PubMed ID: 34000408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic options for COVID-19: an update on current evidence.
    Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
    Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.
    Giesen N; Sprute R; Rüthrich M; Khodamoradi Y; Mellinghoff SC; Beutel G; Lueck C; Koldehoff M; Hentrich M; Sandherr M; von Bergwelt-Baildon M; Wolf HH; Hirsch HH; Wörmann B; Cornely OA; Köhler P; Schalk E; von Lilienfeld-Toal M;
    Eur J Cancer; 2021 Apr; 147():154-160. PubMed ID: 33676266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
    Garraud O
    Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.